Patients who discontinued cancer immunotherapy because of immune-related adverse events (irAEs) often had durable benefits ...

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

The New Jersey-based company's shares fell 1.6% in extended trading. The drug, mavacamten, was tested in adult patients with ...

This was the stock's second consecutive day of losses.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

We recently published a list of 10 Dirt Cheap Stocks To Invest In Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other dirt cheap ...

The stock's fall snapped a two-day winning streak.

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report). The company’s ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and ...